Integrated Advisors Network LLC Grows Holdings in IDEXX Laboratories, Inc. $IDXX

Integrated Advisors Network LLC increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2,797.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,792 shares of the company’s stock after acquiring an additional 9,454 shares during the quarter. Integrated Advisors Network LLC’s holdings in IDEXX Laboratories were worth $5,502,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. SHP Wealth Management purchased a new stake in IDEXX Laboratories in the fourth quarter worth about $26,000. Virtus Advisers LLC purchased a new position in shares of IDEXX Laboratories during the third quarter valued at approximately $26,000. Park Place Capital Corp purchased a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $29,000. WealthCollab LLC bought a new stake in shares of IDEXX Laboratories in the 2nd quarter worth approximately $30,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of IDEXX Laboratories in the 3rd quarter worth approximately $36,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Up 0.1%

IDXX traded up $0.41 during trading on Tuesday, hitting $565.39. 184,525 shares of the company’s stock traded hands, compared to its average volume of 571,344. The stock has a market capitalization of $44.60 billion, a price-to-earnings ratio of 41.75, a PEG ratio of 3.05 and a beta of 1.55. The company’s 50 day simple moving average is $555.31 and its two-hundred day simple moving average is $608.51. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 25th. UBS Group dropped their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Citigroup began coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Finally, Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.